Multicenter, multicohort, open-abel trial (GARNET) dMMR recurrent or advanced endometrial cancer who had progressed on or after a platinum-containing regimen Dostarlimab-gxly q21 (

15 Mar

Breast Cancer

New Indication: Sacituzumab Govitecan for HR+, her2 Negative Breast Cancer

Multicenter, randomized, open-label, phase III Unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer whose disease progressed after a CDK 4/6 inhibit

15 Mar

Prostate Cancer

New Indication: Maintenance Darolutamide for CRPC

Randomized , phase 2 trial Patients with mCRPC who received prior androgen-receptor pathway inhibitors (ARPIs) and subsequently had nonprogressive disease on a taxane Darolutamid

20 Aug

Uterine Cancer

New Protocol: Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma

Single-arm, open-label, multicenter, phase II trial Patients with uLMS, progression on ≥1 prior line treatment Temozolomide +Olaparib (n=22

15 Mar

Bladder Cancer

New Reference: Neoadjuvant CISplatin and Gemcitabine for Urothelial Cancer

Multicenter, single-arm, phase II trial Localized high-grade UTUC or radiographically visible invasive disease Four cycles of split-dose GC (n=57)

15 Mar

Colorectal Cancer

New Protocol: Tucatinib and Trastuzumab for Metastatic Colorectal Cancer

Phase II, open-label, multicenter study Pretreated, HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer Tucatinib + Trastuzumab q21 (n=117)

15 Mar

Non-Small Cell Lung Cancer

New Indication: Adjuvant Pembrolizumab for NSCLC

Randomized, triple-blind, phase III trial Completely resected, pathologically confirmed stage IB (tumours of ≥4 cm in diameter), II, or IIIA Pembrolizumab (n=590) vs PBO (n=587)

15 Mar

Pancreatic Cancer

New Indication: Sotorasib in kRAS G12C Mutant Pancreatic Cancer

International, multicenter, open-label, phase 1–2 trial Pretreated, locally advanced or metastatic pancreatic cancer with KRAS p.G12C mutation Sotorasib (n=38)

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries